OPKO Health, Inc. (OPK) – What Are Brokerages Saying About This Stock?

Shares of OPKO Health, Inc. (NASDAQ:OPK) have been assigned a consensus recommendation of “Moderate Buy” from the seven research firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $3.42.

A number of analysts have commented on the stock. Piper Sandler reiterated an “overweight” rating and issued a $4.00 price objective (up from $3.00) on shares of OPKO Health in a report on Friday, October 16th. UBS Group set a $4.00 target price on shares of OPKO Health in a research report on Friday, October 16th. HC Wainwright reiterated a “buy” rating on shares of OPKO Health in a report on Friday, October 16th. Zacks Research raised OPKO Health from a “hold” rating to a “strong-buy” rating in a research report on Monday, September 28th. Finally, Barrington Research upgraded OPKO Health from a “market perform” rating to an “outperform” rating and set a $2.25 price target on the stock in a report on Friday, October 16th.

OPKO Health Stock Performance

NASDAQ OPK opened at $1.66 on Wednesday. OPKO Health has a 12 month low of $0.98 and a 12 month high of $1.77. The company’s 50-day moving average price is $1.56 and its 200-day moving average price is $1.35. The stock has a market cap of $1.24 billion, a PE ratio of -18.44 and a beta of 1.51. The company has a current ratio of 3.35, a quick ratio of 2.93 and a debt-to-equity ratio of 0.28.

Hedge Funds Weigh In On OPKO Health

A number of hedge funds have recently made changes to their positions in OPK. BlackRock Inc. purchased a new stake in shares of OPKO Health in the 2nd quarter valued at about $55,468,000. AWM Investment Company Inc. acquired a new position in OPKO Health in the second quarter valued at $3,165,000. Bank of New York Mellon Corp purchased a new stake in shares of OPKO Health in the second quarter valued at about $1,995,000. OP Asset Management Ltd acquired a new stake in shares of OPKO Health during the first quarter worth about $1,257,000. Finally, Bank of America Corp DE purchased a new position in shares of OPKO Health during the second quarter worth about $1,194,000. Hedge funds and other institutional investors own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc is a healthcare company focused on diagnostics and pharmaceuticals. Through its BioReference Laboratories business, the company provides clinical laboratory services, including routine testing, specialty diagnostics, genetic testing and oncology-related laboratory services. OPKO also develops diagnostic products, including the 4Kscore test, a blood test designed to help assess the risk of aggressive prostate cancer.

In pharmaceuticals, OPKO develops treatments for kidney disease, endocrine disorders and other conditions.